ClinicalTrials.gg
CompletedNCT05931367TRIUMPH-4Updated Jan 21, 2026

A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee

A Phase 3 interventional study of Retatrutide and Placebo in Obesity, Overweight and Osteo Arthritis Knee, sponsored by Eli Lilly and Company. Completed at 49 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-21.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Nov 2025, 1 year ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
445
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing retatrutide in Obesity — 1 open to participants now, 6 under way, 5 of them phase 3. retatrutide · Obesity.

Enrollment
8th of 16
445 · median 392
Started
2023
with 5 others
Phase 3
9 of 16
none open now
Registered
7th of 16
by date
Lead sponsor
15 of 16
Eli Lilly and Company

Among the 16 studies testing retatrutide in Obesity, this one is the 8th largest by enrollment, is one of 6 that started in 2023, is one of 9 in phase 3, and was the 7th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

1 of the 16 studies testing retatrutide in Obesity is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About retatrutide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing retatrutide in Obesity, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate the safety and efficacy of retatrutide once-weekly in participants who have obesity or are overweight and have osteoarthritis (OA) of the knee. The study will lasts about 77 weeks.

03

Conditions studied

  • Obesity
  • Overweight
  • Osteo Arthritis Knee
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a (BMI) ≥27 kilogram/kg/m² at screening.
  • Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight.
  • Have index knee pain for >12 weeks prior to screening, and presence of index knee pain for >15 days over the previous month.
  • Have knee X-ray with moderate radiographic changes (Kellgren-Lawrence Grade 2 or 3) per central reading at screening.
  • Currently meets American College of Rheumatology (ACR) Criteria (clinical and radiological) for OA.

Exclusion criteria

Exclusion Criteria:

  • Have had joint injections within 90 days of screening.
  • Have had other joint injections and procedures within 6 months of screening.
  • Have joint disease other than osteoarthritis.
  • Have a self-reported or documented change in body weight >5 kg (11 pounds) within 90 days prior to screening.
  • Have been taking weight loss drugs, including over-the-counter medications, within 90 days prior to screening.
  • Have a prior or planned surgical treatment for obesity.
  • Have diabetes mellitus.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
445 participants (actual)

Study arms

  • Experimental
    Retatrutide Dose 1

    Participants will receive retatrutide subcutaneously (SC).

    Drug: Retatrutide

  • Experimental
    Retatrutide Dose 2

    Participants will receive retatrutide SC.

    Drug: Retatrutide

  • Placebo comparator
    Placebo

    Participants will receive placebo.

    Drug: Placebo

Interventions

  • Administered SC

    Also known as: LY3437943

  • DrugPlacebo

    Administered SC

06

What researchers measure

Primary outcomes

  1. Change from Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score

    Time frame: Baseline, Week 68

  2. Percent Change from Baseline in Body Weight

    Time frame: Baseline, Week 68

Secondary outcomes

  1. Change from Baseline in the WOMAC Physical Function Subscale Score

    Time frame: Baseline, Week 68

  2. Change from Baseline in Waist Circumference

    Time frame: Baseline, Week 68

  3. Percent Change from Baseline in Total Cholesterol

    Time frame: Baseline, Week 68

  4. Percent Change from Baseline in Triglycerides

    Time frame: Baseline, Week 68

  5. Change from Baseline in Body Mass Index (BMI)

    Time frame: Baseline, Week 68

  6. Change from Baseline in Systolic Blood Pressure (SBP)

    Time frame: Baseline, Week 68

  7. Change from Baseline in Diastolic Blood Pressure (DBP)

    Time frame: Baseline, Week 68

  8. Percent Change from Baseline in Fasting Insulin

    Time frame: Baseline, Week 68

  9. Change from Baseline in Short Form 36-Version 2 (SF-36v2) Acute Form Physical Functioning Domain Score

    Time frame: Baseline, Week 68

  10. Change from Baseline in Average Pain Intensity Numeric Rating Score (API-NRS) Score

    Time frame: Baseline, Week 68

  11. Change from Baseline in Worst Pain Intensity Numeric Rating Score (WPI-NRS) Score

    Time frame: Baseline, Week 68

07

Study locations

49 sites
  • Arizona Research Center
    Phoenix, Arizona 85053, United States
  • Artemis Institute for Clinical Research
    San Diego, California 92103, United States
  • Chase Medical Research, LLC
    Waterbury, Connecticut 06708, United States
  • Suncoast Research Group
    Miami, Florida 33135, United States
  • North Georgia Clinical Research
    Woodstock, Georgia 30189, United States
  • Elite Clinical Trials
    Blackfoot, Idaho 83221, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • MedVadis Research Corporation
    Waltham, Massachusetts 02451, United States
  • Great Lakes Research Group, Inc.
    Bay City, Michigan 48706, United States
  • Clinvest Research LLC
    Springfield, Missouri 65807, United States
  • Mercy Family Clinic
    Dallas, Texas 75211, United States
  • Clinical Trials of Texas, Inc.
    San Antonio, Texas 78229, United States
  • Northwest Clinical Research Center
    Bellevue, Washington 98007, United States
  • Paratus Clinical Research Canberra
    Bruce, Australian Capital Territory 2617, Australia
  • Paratus Clinical Research Western Sydney
    Blacktown, New South Wales 2148, Australia
  • Emeritus Research
    Botany, New South Wales 2019, Australia
  • Royal Brisbane and Women's Hospital
    Brisbane, Queensland 4029, Australia
  • Core Research Group
    Brisbane, Queensland 4064, Australia
  • CDH Research Institute
    Maroochydore, Queensland 4558, Australia
  • Emeritus Research
    Camberwell, Victoria 3124, Australia
  • Barwon Health
    Geelong, Victoria 3220, Australia
  • C-health Research
    Calgary, Alberta T2V 4J2, Canada
  • Eastern Health - General Hospital
    St. John's, Newfoundland and Labrador A1B 3V6, Canada
  • Viable Clinical Research
    Bridgewater, Nova Scotia B4V 3N2, Canada
  • Wharton Medical Clinic
    Hamilton, Ontario L8L 5G8, Canada
  • Bluewater Clinical Research Group Inc.
    Sarnia, Ontario N7T 4X3, Canada
  • Viable Clinical Research
    Scarborough Village, Ontario M1P 2T7, Canada
  • Stouffville Medical Research Institute Inc.
    Stouffville, Ontario L4A 1H2, Canada
  • Canadian Phase Onward
    Toronto, Ontario M3J 0K2, Canada
  • Alpha Recherche Clinique
    Québec, G2J 0C4, Canada
  • ALPHA Recherche Clinique
    Québec, G3K 2P8, Canada
  • Consultorio Médico
    Guadalajara, Jalisco 44210, Mexico
  • IMED Internal Medicine Clin Trials
    Monterrey, Nuevo León 64020, Mexico
  • Clínica García Flores SC
    Monterrey, Nuevo León 64610, Mexico
  • Unidad Médica para la Salud Integral
    San Nicolás de los Garza, Nuevo León 66465, Mexico
  • Centro de Estudios de Investigacion Metabolicos y Cardiovasculares
    Ciudad Madero, Tamaulipas 89440, Mexico
  • Kohler and Milstein Research S.A. de C.V.
    Mérida, Yucatán 97070, Mexico
  • Investigacion y Biomedicina de Chihuahua
    Chihuahua City, 31000, Mexico
  • Complejo Hospitalario Universitario de Ferrol (CHUF)- Hospital Naval")
    Ferrol, A Coruña 15405, Spain
  • Hospital Universitario Reina Sofia
    Córdoba, Andalusia 14004, Spain
  • Hospital Quirón Málaga
    Málaga, Andalusia 29004, Spain
  • Hospital de la Santa Creu i Sant Pau
    Barcelona, Catalonia 08041, Spain
  • Hospital Universitario Infanta Sofía
    San Sebastián de los Reyes, Madrid 28702, Spain
  • Hospital General Universitario de Valencia
    Valencia, Valenciana 46014, Spain
  • CHUAC-Complejo Hospitalario Universitario A Coruña
    A Coruña, 15006, Spain
  • Clínica nuevas Tecnologías en Diabetes y Endocrinología (NTDE)
    Seville, 41003, Spain
  • Leicester General Hospital
    Leicester, Leicestershire LE5 4PW, United Kingdom
  • Panthera Biopartners - North London
    Enfield, London EN3 4GS, United Kingdom
  • Panthera Biopartners - Sheffield
    Sheffield, S2 5FX, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2023 to primary completion in Nov 2025, 27 months.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 27 months is above that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2023
First posted
Jul 5, 2023
StartActual
Aug 1, 2023
Primary completionActual
Nov 14, 2025
CompletionActual
Nov 14, 2025
Last update
Jan 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05931367
Responsible party
Sponsor
First posted
Jul 5, 2023
Start date
Aug 1, 2023
Primary completion
Nov 14, 2025
Completion
Nov 14, 2025
Last update
Jan 21, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Retatrutide

Start the discussion